Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2 Positive Breast Cancer
Interventions: DRUG: Pyrotinib plus trastuzumab and docetaxel and carboplatin
Sponsor: Henan Cancer Hospital